ComplianceOnline

Lack of Robust Regulations for Generic Drugs Warning Labels Leads to Outcry

  • By: Staff Editor
  • Date: May 03, 2012
Webinar All Access Pass Subscription Abstract:

An original drug manufacturer seeking new drug approval from the FDA is responsible for accurately and adequately labeling the new drug. A manufacturer of a generic drug is only responsible for making sure its warning label is the same as the reference drug. This has led to an outcry from patients and drug manufacturers as generics makers cannot be held legally responsible for any product defects. Both groups are demanding a change in current generics warning label regulations by the FDA.

Bookmark and Share

Trending Compliance Trainings

Challenges of an Effective Change Control Program
By - Kenneth Christie
On Demand Access Anytime
Implementation and Management of GMP Data Integrity
By - Danielle DeLucy
On Demand Access Anytime
FDA Compliance and Clinical Trial Computer System Validation
By - Carolyn Troiano
On Demand Access Anytime
Biocompatibility Testing; what you need to know
By - Mike Colvin
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading